MHCSeqNet: a deep neural network model for universal MHC binding prediction.

Journal: BMC bioinformatics
Published Date:

Abstract

BACKGROUND: Immunotherapy is an emerging approach in cancer treatment that activates the host immune system to destroy cancer cells expressing unique peptide signatures (neoepitopes). Administrations of cancer-specific neoepitopes in the form of synthetic peptide vaccine have been proven effective in both mouse models and human patients. Because only a tiny fraction of cancer-specific neoepitopes actually elicits immune response, selection of potent, immunogenic neoepitopes remains a challenging step in cancer vaccine development. A basic approach for immunogenicity prediction is based on the premise that effective neoepitope should bind with the Major Histocompatibility Complex (MHC) with high affinity.

Authors

  • Poomarin Phloyphisut
    Department of Computer Engineering, Faculty of Engineering, Chulalongkorn University, 254 Phayathai Road, Pathumwan, Bangkok, 10330, Thailand.
  • Natapol Pornputtapong
    Department of Biochemistry and Microbiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, 254 Phayathai Road, Pathumwan, Bangkok, 10330, Thailand. natapol.p@chula.ac.th.
  • Sira Sriswasdi
    Research Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Ekapol Chuangsuwanich
    Department of Computer Engineering, Faculty of Engineering, Chulalongkorn University, 254 Phayathai Road, Pathumwan, Bangkok, 10330, Thailand. ekapol.c@chula.ac.th.